Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials.
Dawn M
DM
Torres
Stephen A
SA
Harrison
D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*
C552098:2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003841:Deoxycytidine; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a